logo
Plus   Neg
Share
Email

Sanofi Q1 Profit Rises; Backs 2019 Business EPS Outlook - Quick Facts

French drug giant Sanofi SA (SNYNF,SNY) reported Friday that its net income attributable to equity holders for the first quarter of 2019 rose to 1.14 billion euros from last year's 1.02 billion euros, with earnings per share rising to 0.91 euros from 0.81 euros in the prior year.

Net income, excluding the held for exchange Animal Health business, increased to 1.15 billion euros from 1.05 billion euros in the prior year. Earnings per share, excluding the held for exchange AnimalHealth business, were 0.91 euros, up from 0.81 euros in the previous year.

First-quarter business net income increased 10.5 percent to 1.77 billion euros, and increased 9 percent at CER. Business earnings per share rose 10.9 percent to 1.42 euros on a reported basis, and increased 9.4 percent at CER.

Quarterly sales increased 6.2 percent to 8.39 billion euros from 7.90 billion euros in the year-ago quarter. At CER, company sales grew 4.2 percent.

Exchange rate movements had a positive effect of 2.0 percentage points mainly driven by the U.S. dollar, which largely offset the negative impact from the Argentine Peso, Turkish Lira, Brazilian Real and Russian Ruble.

Looking ahead to fiscal 2019, Sanofi said it continues to expect business earnings per share to grow between 3 percent and 5 percent at CER, barring unforeseen major adverse events. Applying the average April 2019 exchange rates, the company estimates the currency impact on 2019 business earnings per share to be around 2 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
A new research has found unusual increase in malware, as cyber criminals find new avenues to attack. WatchGuard Technologies on Tuesday released its quarterly Internet Security Report for first quarter. The report says malware detections in the first quarter surged a massive 62% from previous quarter. The... A study has suggested that the risk of dementia is stronger in older adults on the use of anticholinergic drugs, highlighting the importance of reducing exposure to anticholinergic drugs in middle-aged and older people. Anticholinergic drugs work by blocking the action of a neurotransmitter called acetylcholine. This inhibits nerve impulses responsible for involuntary muscle movements. Norway's $1 trillion sovereign wealth fund, the world's largest, has been given the approval to invest again in retail giant Walmart Inc. and miner Rio Tinto plc, among other companies. This follows the Norway central bank's decision to revoke these companies' exclusions from the fund's investments on ethical grounds. Walmart was excluded in 2006 from the pension fund's investments.
Follow RTT